Advertisement
The PLoS Medicine Debate

The PLoS Medicine Debate The PLOS Medicine Debate discusses important but controversial issues in clinical practice, public health policy, or health in general. Debates will be commissioned from two or more authors with differing points of view.

See all article types »

What Is the Optimal Therapy for Patients with H5N1 Influenza?

  • Nicholas J. White mail,

    nickwdt@tropmedres.ac (NJW); robert.webster@stjude.org (RGW); tuyeki@cdc.gov (TMU)

    Affiliation: Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

    X
  • Robert G. Webster mail,

    nickwdt@tropmedres.ac (NJW); robert.webster@stjude.org (RGW); tuyeki@cdc.gov (TMU)

    Affiliation: Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America

    X
  • Elena A. Govorkova,

    Affiliation: Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America

    X
  • Timothy M. Uyeki mail

    nickwdt@tropmedres.ac (NJW); robert.webster@stjude.org (RGW); tuyeki@cdc.gov (TMU)

    Affiliation: Epidemiology and Prevention Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

    X
  • Published: June 23, 2009
  • DOI: 10.1371/journal.pmed.1000091

About the Authors

Nicholas J. White
Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
Robert G. Webster, Elena A. Govorkova
Department of Infectious Diseases, Division of Virology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America
Timothy M. Uyeki
Epidemiology and Prevention Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America

Corresponding Authors

Competing Interests

NJW is the co-chairman of the World Health Organization antimalarial treatment guidelines committee. RGW reports receiving research funding from Hoffmann-La Roche and BioCryst Pharmaceuticals and receiving consulting fees from GlaxoSmithKline. EAG reports receiving research funding from Hoffmann-La Roche and BioCryst Pharmaceuticals.

Author Contributions

ICMJE criteria for authorship read and met: NJW RGW EAG TMU. Contributed to the writing of the paper: NJW RGW EAG TMU.